Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1, open-label randomized crossover trial in Healthy Volunteers to evaluate the PK/PD of TI (Technosphere® Insulin) prepared with insulin from two different suppliers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mannkind Corporation
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Men and women aged 18 to 55 years, considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis

• HNVs with a screening blood pressure less than 140/90 mm Hg

• Subjects who have hypertension controlled with up to 1 medication and who have a blood pressure less than 140/90 mm Hg

• Note: For subjects with blood pressure at or above 140/90 mm Hg; two additional readings 5 minutes apart are allowed but the last blood pressure reading must be in range

• Subjects who have hypercholesterolemia controlled with up to 1 medication and who have a low-density lipoprotein value less than 160 mg/dL

• Good venous access for blood draws

• No smoking in the past 6 months (including cigarettes, cigars, and pipes) and urine cotinine testing < 100 ng/mL

• Body mass index (BMI) < 32 kg/m2

• Completion of informed consent form

Exclusion Criteria:

• Blood donation (500 mL) within the last 8 weeks

• Fasting blood sugar >100 mg/dL

• History of coronary artery disease, peripheral vascular disease, or congestive heart failure

• Allergy to study drug, components of Boost and Boost Plus, or other study material

• Clinically significant active or chronic illness

• History of asthma, COPD, or any other clinically relevant chronic lung disease

• Respiratory tract infection within 4 weeks before screening

• History of drug or alcohol abuse within the past 5 years

• Positive urine drug screen

• Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality

• Exposure to any other investigational drug or device within 30 days before treatment or within 90 days before treatment for drugs known to modify glucose metabolism

• History of malignancy within the 5 years before screening (other than basal cell carcinoma)

• History of human immunodeficiency virus (HIV) infection or hepatitis B or C

• Women who are pregnant, lactating, or planning to become pregnant during the clinical study period

• Women of childbearing potential (premenopausal who have not undergone hysterectomy or bilateral tubal ligation, or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for the purposes of this clinical study includes experiencing amenorrhea for 2 or more years or being surgically sterile.

• Any subject who, in the opinion of the PI or a designee, appears not to be qualified for this study